These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12581326)

  • 1. Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients.
    Argent E; Kainer G; Aitken M; Rosenberg AR; Mackie FE
    Pediatr Transplant; 2003 Feb; 7(1):38-42. PubMed ID: 12581326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
    Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
    Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indications and outcome of treatment of hyperlipidemia in pediatric allograft recipients.
    Silverstein DM
    Pediatr Transplant; 2003 Feb; 7(1):7-10. PubMed ID: 12581321
    [No Abstract]   [Full Text] [Related]  

  • 5. Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins.
    Romero R; Calviño J; Rodriguez J; Sánchez-Guisande D
    Nephrol Dial Transplant; 2000 Sep; 15(9):1446-9. PubMed ID: 10978406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.
    Renders L; Mayer-Kadner I; Koch C; Schärffe S; Burkhardt K; Veelken R; Schmieder RE; Hauser IA
    Nephrol Dial Transplant; 2001 Jan; 16(1):141-6. PubMed ID: 11209008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study.
    Aguilar-Salinas CA; Gómez-Pérez FJ; Posadas-Romero C; Vázquez-Chávez C; Meaney E; Gulías-Herrero A; Guillén LE; Alvarado Vega A; Mendoza Pérez E; Eduardo Romero-Nava L; Angélica Gómez-Díaz R; Salinas-Orozco S; Moguel R; Novoa G
    Atherosclerosis; 2000 Oct; 152(2):489-96. PubMed ID: 10998478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
    McKenney JM; McCormick LS; Weiss S; Koren M; Kafonek S; Black DM
    Am J Med; 1998 Feb; 104(2):137-43. PubMed ID: 9528731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of fluvastatin on hyperlipidemia after renal transplantation.
    Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
    Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.
    Hunninghake D; Bakker-Arkema RG; Wigand JP; Drehobl M; Schrott H; Early JL; Abdallah P; McBride S; Black DM
    J Fam Pract; 1998 Nov; 47(5):349-56. PubMed ID: 9834769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
    Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
    J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study.
    Schrott HG; Knapp H; Davila M; Shurzinske L; Black D
    Am Heart J; 2000 Aug; 140(2):249-52. PubMed ID: 10925339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
    Gentile S; Turco S; Guarino G; Sasso CF; Amodio M; Magliano P; Salvatore T; Corigliano G; Agrusta M; De Simone G; Gaeta I; Oliviero B; Torella R
    Diabetes Obes Metab; 2000 Dec; 2(6):355-62. PubMed ID: 11225965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.
    Ooi TC; Heinonen T; Alaupovic P; Davignon J; Leiter L; Lupien PJ; Sniderman AD; Tan MH; Tremblay G; Sorisky A; Shurzinske L; Black DM
    Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1793-9. PubMed ID: 9327779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
    Li XP; Duan J; Zhao SP; Tan MY; Xu ZM; Zhang DQ
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2399-403. PubMed ID: 17156651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.
    Harris KP; Wheeler DC; Chong CC;
    Kidney Int; 2002 Apr; 61(4):1469-74. PubMed ID: 11918754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
    Alaupovic P; Heinonen T; Shurzinske L; Black DM
    Atherosclerosis; 1997 Aug; 133(1):123-33. PubMed ID: 9258416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial).
    März W; Wollschläger H; Klein G; Neiss A; Wehling M
    Am J Cardiol; 1999 Jul; 84(1):7-13. PubMed ID: 10404843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.